# Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates

> **NCT00961753** · PHASE4 · TERMINATED · sponsor: **OSF Healthcare System** · enrollment: 10 (actual)

## Conditions studied

- Patent Ductus Arteriosus

## Interventions

- **DRUG:** optimized ibuprofen
- **DRUG:** Standard Ibuprofen

## Key facts

- **NCT ID:** NCT00961753
- **Lead sponsor:** OSF Healthcare System
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** FDA drug recall on July 30, 2010
- **Last updated:** 2014-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00961753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00961753, "Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00961753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*